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Background These two trials under Europe-Africa collabora-
tions aim at addressing two factors relevant for Africa i.e hel-
minth infections and HIV-1 diversity. EV06 used a novel
combination of DNA expressing clade C Env, Gag and Pol-nef
co-administered with AIDSVAX®B/E Env protein to study the
effect of S. mansoni on vaccine responses. GREAT is a recently
awarded trial using a 2nd generation improved conserved
tHIVConsvX T-cell vaccine candidate combined with bivalent
mosaic design to increase breadth and protective epitopes.
Methods EV06 enrolled 72 males and females aged 18–45,
half infected with S. mansoni (SM+). In each arm 30 received
vaccine and 6 placebo at week 0, 4 and 24. Responses were
evaluated at week 0, 6, 26 and 36. Humoral responses were
measured as binding IgG against a panel of HIV-1 envelope gly-
coproteins and as neutralizing antibodies (Nabs), using TZM/ bl
cells and tier 1 pseudoviruses. Cellular responses were measured
as HIV-speciﬁc CD4+ and CD8+ T-cell by IFN-γ ELIS-pot and
multi-cytokine intracellular staining ﬂow cytometry. GREATwill
be a phase IIa trial and preparation for efﬁcacy trials in Kenya,
Uganda and Zambia testing ChAdOx1.tHIVconsv5 and
ChAdOx1.tHIVconsv6 followed by MVA.tHIVconsv3 and
MVA.tHIVconsv4 on week 2 (Arm 1) or week 8 (Arm 2).
Progress Differences in binding IgG response rates were
observed in vaccinated participants against the vaccine matched
clade C V1V2 (gp70–96ZM651.02 V1V2) at week 6: 56%
among SM+ versus 86% among SM – (p=0.039). At week 36,
response magnitudes were statistically lower in the SM+ against
gp120 and gp140 proteins (p=0.04 for both). SM+ also had
lower Nabs and ELISpot responses at various time points. Still
blinded data on the ﬁrst 20 volunteers show 80% responders
for CD4 T cell at w26 and 70% CD8 responders at w36. These
trials will provide more data on challenges facing HIV vaccine
development in Africa.
A16 BMJ Glob Health 2017;2(Suppl 2):A1–A67
Abstracts
 o
n
 22 January 2019 by guest. Protected by copyright.
http://gh.bmj.com/
BM
J G
lob Health: first published as 10.1136/bmjgh-2016-000260.39 on 12 February 2017. Downloaded from 
